New treatment for aggressive triple-negative breast cancer using a dual-payload antibody-drug conjugate
Dual-payload antibody-drug conjugate for chemo-immunotherapy of triple-negative breast cancers
This study is testing a new treatment for triple-negative breast cancer that combines chemotherapy and immunotherapy to better target cancer cells and boost the immune system, and it's designed for patients looking for more effective options against this tough type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10893502 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for triple-negative breast cancer (TNBC) that combines chemotherapy with immunotherapy. The approach utilizes a dual-payload antibody-drug conjugate designed to target specific cancer cells while enhancing the immune response against the tumor. By using a humanized monoclonal antibody that targets CD276, the treatment aims to overcome resistance to existing therapies and significantly reduce tumor size and metastasis. The research involves preclinical evaluations in animal models to assess the effectiveness of this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have not responded to standard treatments.
Not a fit: Patients with non-triple-negative breast cancers or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with triple-negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise in using antibody-drug conjugates and immunotherapy for cancer treatment, indicating that this approach could be a significant advancement in the field.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Liu, Xiaoguang Margaret — Ohio State University
- Study coordinator: Liu, Xiaoguang Margaret
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.